Oppenheimer resumed coverage on DermTech with a new price target
$DMTK
Medical Specialities
Health Care
Oppenheimer resumed coverage of DermTech with a rating of Buy and set a new price target of $58.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | $48.00 | Outperform | Oppenheimer |
| 6/14/2022 | $38.00 → $19.00 | Buy | BTIG Research |
| 1/7/2022 | $26.00 | Overweight | Stephens |
| 1/7/2022 | Overweight | Stephens & Co. | |
| 10/15/2021 | $50.00 | Outperform | Cowen |
Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00
BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously
Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00